4//SEC Filing
NPS PHARMACEUTICALS INC 4
Accession 0001104659-15-013584
CIK 0000890465operating
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 9:16 PM ET
Size
12.8 KB
Accession
0001104659-15-013584
Insider Transaction Report
Form 4
Broom Colin MD
Director
Transactions
- Disposition from Tender
Common Stock
2015-02-21$46.00/sh−24,313$1,118,398→ 0 total - Disposition to Issuer
Restricted Stock Units
2015-02-21−3,816→ 0 total→ Common Stock (3,816 underlying) - Disposition to Issuer
Stock Options (right to buy)
2015-02-21−36,000→ 0 totalExercise: $4.95Exp: 2019-07-09→ Common Stock (36,000 underlying) - Disposition to Issuer
Deferred Stock Units
2015-02-21−29,759→ 0 total→ Common Stock (29,759 underlying)
Footnotes (8)
- [F1]On July 9, 2009, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
- [F2]In connection with the merger of Knight Newco 2, Inc. with and into NPS Pharmaceuticals, Inc. (the "Issuer") on February 21, 2015, each outstanding stock option, whether vested or unvested, was cancelled in exchange for a single lump sum cash payment in an amount equal to the product of (1) the number of shares of the Issuer's common stock subject to such stock option and (2) the execess, if any, of $46.00 over the exercise price per share of such stock option.
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.
- [F4]On February 12, 2015, the Restricted Stock Units were granted with one hundred percent vesting on the first anniversary of date of grant.
- [F5]In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Restricted Stock Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Restricted Stock Unit.
- [F6]Each Deferred Stock Unit represents a right to receive one share of the Issuer's common stock.
- [F7]Deferred Stock Units are vested in full on the date of grant and will be settled in the Issuer's common stock upon (1) separation from service on the Board, (2) death, (3) disability or (4) a sale of substantially all the assets of the Issuer.
- [F8]In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Deferred Stock Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Deferred Stock Unit.
Documents
Issuer
NPS PHARMACEUTICALS INC
CIK 0000890465
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000890465
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 9:16 PM ET
- Size
- 12.8 KB